$CEL-SCI (CVM.US)$ CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market Wednesday, 23rd April at 8:30 am • Concluded a successful meeting with Saudi Food and Drug Authority • CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3 study • Evaluating Saudi Arabia-based partnerships to ...
$CEL-SCI (CVM.US)$ New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses Tuesday, 8th April at 9:51 am Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival A third-p...
$CEL-SCI (CVM.US)$ CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine Monday, 17th March at 8:00 am Growing body of data on PD-L1 as a cancer biomarker spurs interest Working towards partnership for non-dilutive funding of the final confirmatory head and neck cancer Registration Study CEL-SCI Corporation (NYSE: CVM) today announced it received comments from the U.S. Food and Drug Administra...
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
CEL-SCI Stock Discussion
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
Wednesday, 23rd April at 8:30 am
• Concluded a successful meeting with Saudi Food and Drug Authority
• CEL-SCI was encouraged to apply for Conditional Approval with Breakthrough Therapy Designation based on data from its concluded Phase 3 study
• Evaluating Saudi Arabia-based partnerships to ...
Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
Tuesday, 8th April at 9:51 am
Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival
A third-p...
Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients
CEL-SCI Cancer Treatment Shows 73% Survival Rate, FDA Clears Path to Market
CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
Monday, 17th March at 8:00 am
Growing body of data on PD-L1 as a cancer biomarker spurs interest
Working towards partnership for non-dilutive funding of the final confirmatory head and neck cancer Registration Study
CEL-SCI Corporation (NYSE: CVM) today announced it received comments from the U.S. Food and Drug Administra...
Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer
No comment yet